Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Aytu Biopharma (AYTU) Convertible Debt: 2015-2016

Aytu Biopharma's Convertible Debt was N/A to $5.2 million in Q2 2016 from the same period last year, while for Jun 2016 it was $5.2 million, marking a year-over-year change of. This contributed to the annual value of $5.2 million for FY2016, which is N/A change from last year.
Latest data reveals that Aytu Biopharma reported Convertible Debt of $5.2 million as of Q2 2016, which was up 52,722.29% from $9,797 recorded in Q1 2016.
Aytu Biopharma's 5-year Convertible Debt high stood at $5.2 million for Q2 2016, and its period low was $9,797 during Q1 2016.
In the last 2 years, Aytu Biopharma's Convertible Debt had a median value of $4.9 million in 2015 and averaged $3.7 million.